Evidence map›Paper›PMID 42642447›Full record

ArticleScientific reports2026

MicroRNA profiles of prostate cancer bone metastases and miR-375 as an inhibitor of the aggressive metastasis subtype MetB.

Helena Järemo, Julius Semenas, Sofia Halin Bergström, Elin Thysell, Marie Lundholm, Eva Freyhult, Andreas Josefsson, Karin Welén, Camilla Thellenberg Karlsson, Sead Crnalic and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Helena JäremoDepartment of Medical Biosciences, Pathology, Umeå University, 901 87, Umeå, Sweden.
Julius SemenasDepartment of Medical Biosciences, Pathology, Umeå University, 901 87, Umeå, Sweden.
Sofia Halin BergströmDepartment of Medical Biosciences, Pathology, Umeå University, 901 87, Umeå, Sweden.
Elin ThysellDepartment of Medical Biosciences, Pathology, Umeå University, 901 87, Umeå, Sweden.
Marie LundholmDepartment of Medical Biosciences, Pathology, Umeå University, 901 87, Umeå, Sweden.
Eva FreyhultScience for Life Laboratory, Department of Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden, Uppsala University, Uppsala, Sweden.
Andreas JosefssonDepartment of Diagnostics and Intervention, Urology and Andrology, Umeå University, 901 87, Umeå, Sweden.
Karin WelénDepartment of Urology, Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Camilla Thellenberg KarlssonDepartment of Diagnostics and Intervention, Oncology, Umeå University, 901 87, Umeå, Sweden.
Sead CrnalicDepartment of Diagnostics and Intervention, Orthopaedics, Umeå University, 901 87, Umeå, Sweden.
Anders BerghDepartment of Medical Biosciences, Pathology, Umeå University, 901 87, Umeå, Sweden.
Maria BrattsandDepartment of Medical Biosciences, Pathology, Umeå University, 901 87, Umeå, Sweden.
Pernilla WikströmDepartment of Medical Biosciences, Pathology, Umeå University, 901 87, Umeå, Sweden. pernilla.wikstrom@umu.se.ORCID 0000-0002-6347-1999

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel treatments for metastatic prostate cancer (PC) are needed. Molecular subtypes of bone metastatic PC (MetA-C) were recently identified, with the proliferation-driven MetB subtype linked to very poor prognosis. Non-coding microRNAs (miRs) regulate gene expression and constitute potential therapeutic targets. This study aimed to explore miR profiles in bone metastases in relation to the MetA-C subtypes, with focus on the aggressive MetB subtype. Genome-wide microarray analysis of clinical bone metastasis samples (n = 96, 62 patients) identified miR-375 to be inversely associated with the MetB subtype. The metastatic C4-2B cell line was transduced to overexpress or sequester miR-375 and effects were evaluated by microarray analysis, cell proliferation/adhesion assays, and tumor growth in mice. miR-375 overexpression in C4-2B altered transcription profiles and shifted the phenotype from being MetB-like to becoming MetA-like. In cell culture, miR-375 overexpression reduced cell proliferation, increased adhesion, and downregulated YAP1 expression among other direct gene targets, while miR-375 inhibition had opposite effects. In mice, miR-375 overexpression reduced tumor establishment and growth. Our data link clinical and experimental findings of miR-375 being a potential inhibitor of the aggressive MetB subtype in PC.

Indexed as

Bone NeoplasmsMicroRNAsProstatic NeoplasmsAnimalsCell AdhesionCell Line, TumorCell ProliferationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiceMicroRNAsMIRN375 microRNA, humanMetastasismicroRNAmiR-375Prostate cancerSubtypes MetA-C

Identifiers

PMID42642447
PMCPMC13507049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.